Critical appraisal of bevacizumab in the treatment of ovarian cancer

被引：20
作者：
Yoshida, Hiroyuki [1 ]
Yabuno, Akira [1 ]
Fujiwara, Keiichi [1 ]
机构：
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Hidaka City, Saitama 3501298, Japan
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2015年 / 9卷
关键词：
anti-angiogenesis; chemotherapy; biomarkers; EPITHELIAL OVARIAN; TRIAL; CHEMOTHERAPY; PERITONEAL; NEOPLASMS; SURVIVAL; OUTCOMES; VEGF;
D O I：
10.2147/DDDT.S83275
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy for first-line treatment of advanced ovarian cancer. Additional Phase III trials evaluated bevacizumab combined with cytotoxic chemotherapy in platinum-sensitive and platinum-resistant recurrent ovarian cancer. All these trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, bevacizumab effectively improved the quality of life with regard to abdominal symptoms in recurrent ovarian cancer patients. Bevacizumab is associated with adverse events not commonly observed with cytotoxic agents used to treat gynecological cancers, such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed by gynecologists. The clinical trial results with bevacizumab have supported its recent approval in Europe and the United States as a treatment for ovarian cancer. This review presents the latest evidence for bevacizumab therapy of ovarian cancer and describes selection of patients for personalized treatment.
引用
收藏
页码：2351 / 2357
页数：7
相关论文
共 31 条
  • [1] Aghajanian C, 2012, ESMO C
  • [2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [3] AGO Study Group, EV OPT IN TREATM DUR
  • [4] [Anonymous], ISRN OBSTET GYNECOL
  • [5] [Anonymous], J CLIN ONCOL S
  • [6] Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer
    Barnett, Jason C.
    Secord, Angeles Alvarez
    Cohn, David E.
    Leath, Charles A., III
    Myers, Evan R.
    Havrilesky, Laura J.
    [J]. CANCER, 2013, 119 (20) : 3653 - 3661
  • [7] Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop
    Bast, Robert C.
    Thigpen, J. Tate
    Arbuck, Susan G.
    Basen-Engquist, Karen
    Burke, Laurie B.
    Freedman, Ralph
    Horning, Sandra J.
    Ozols, Robert
    Rustin, Gordon J.
    Spriggs, David
    Wenzel, Lari B.
    Pazdur, Richard
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 173 - 176
  • [8] Integrated genomic analyses of ovarian carcinoma
    Bell, D.
    Berchuck, A.
    Birrer, M.
    Chien, J.
    Cramer, D. W.
    Dao, F.
    Dhir, R.
    DiSaia, P.
    Gabra, H.
    Glenn, P.
    Godwin, A. K.
    Gross, J.
    Hartmann, L.
    Huang, M.
    Huntsman, D. G.
    Iacocca, M.
    Imielinski, M.
    Kalloger, S.
    Karlan, B. Y.
    Levine, D. A.
    Mills, G. B.
    Morrison, C.
    Mutch, D.
    Olvera, N.
    Orsulic, S.
    Park, K.
    Petrelli, N.
    Rabeno, B.
    Rader, J. S.
    Sikic, B. I.
    Smith-McCune, K.
    Sood, A. K.
    Bowtell, D.
    Penny, R.
    Testa, J. R.
    Chang, K.
    Dinh, H. H.
    Drummond, J. A.
    Fowler, G.
    Gunaratne, P.
    Hawes, A. C.
    Kovar, C. L.
    Lewis, L. R.
    Morgan, M. B.
    Newsham, I. F.
    Santibanez, J.
    Reid, J. G.
    Trevino, L. R.
    Wu, Y. -Q.
    Wang, M.
    [J]. NATURE, 2011, 474 (7353) : 609 - 615
  • [9] Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
    Broglio, Kristine R.
    Berry, Donald A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1642 - 1649
  • [10] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
1234